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Introduction
Medulloblastomas, infratentorial or cerebellar, primi-
tive neuroectodermal tumors (PNETs) account for 20% of all
childhood brain tumors and 40% of all cerebellar tumors 
1, 2.
Peak occurrence is at 4 years of age. Approximately 10% to
15% are diagnosed in infancy and require specific treatment
approach 
3. Treatment protocols are based on risk stratifica-
tion, which takes into account age at presentation, residual
disease [residual tumor at the primary site after surgery
measured by postoperative gadolinium – enhanced magnetic
resonance imaging (MRI)] as well as evidence of dissemi-
nated disease at the time of diagnosis. Patients older than 3
years of age with minimal residual disease (if postoperative
MRI showed residual disease of 1.5 cm
2 or less) are classi-
fied as an average risk group. Patients are defined as high-
risk group if they had metastatic disease at the time of diag-
nosis (confirmed by gadolinium-enhanced MRI of the head
and spine and if lumbar cerebrospinal fluid assessed after re-
section contained tumor cells); if they had residual disease of
more than 1.5 cm
2 (measured by postoperative gadolinium –
enhanced MRI); if they are younger than 3 years of age at the
time of diagnosis.
Over the past decades there has been progressive im-
provement in the results of treatment of this group of patients
with overall survival rates higher than 70%
 4.
There are several reasons for this which include ad-
vances in neuro-radiological imaging leading to more accu-
rate localization, improvements in neuro-surgical techniques,
better perioperative care, improvement in radiotherapy
equipment and techniques including greater and more precise
dosage delivered to the tumor and refinements in the timing
and dosing of chemotherapy
 5.
Treatment options
Surgery
Surgical resection remains the mainstay of therapy with
the goal of gross total resection (GTR). All patients who pres-
ent with a posterior fossa tumor will undergo an open craniot-
omy. Studies have shown that patients with less then 1.5 cm
2
residual disease had improved survival
 6–8. Some patients
might require a ventricular shunt or third ventriculostomy prior
to resection of the tumor. The majority of patients will have
resolution of the hydrocephalus after tumor resection, but ap-
proximately 40% will require permanent shunt placement.
Prognostic factors for permanent shunting are young age, sig-
nificant pre-surgical hydrocephalus and large tumors 
9.
For most patients, treatment started within 28 days of
surgery, the extent of which was defined as: gross total resec-
tion if followed by no evidence of residual disease; near-total
resection if postoperative MRI showed residual disease of 1.5
cm
2 or less; and subtotal resection if 25% or more of the tumor
remained. The extent of resection is defined by using the neu-
rosurgeons operative notes and by postoperative MRI.
Postsurgical complication characteristically developing
after posterior fossa tumor resection is the cerebellar mutism
syndrome (CMS) also referred to as the posterior fossa syn-
drome. This entity typically starts within 1 to 2 days after
surgery, persists for weeks to months and consists of paucity
of speech leading to mutism, hypotonia, ataxia and emotional
instability. In addition, brainstem dysfunction can be seen,
including dysphagia, facial weakness and abducens paralysis.
In a large study of 450 children, CMS developed after sur-
gery in 107 (24%). Only brainsteam involvement was pre-
dictive for the development of CMS 
10. Another series ana-
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All of these cases had brainsteam involvement 
11. Evidence
of hydrocephalus also appears to exacerbate the development
of CMS 
12. Individual case studies report on successful use of
dopamine agonists, such as bromocriptine for the treatment
of CMS but unfortunately children are often left with dysar-
thic speech 
13, 14. Therefore, careful resection is recom-
mended, especially in children with brainstem involvement.
Radiation therapy
Radiation therapy was the first adjuvant treatment for
brain tumors and was initially applied to the treatment of
adult gliomas and pituitary tumors in the early 1900s. It re-
mains very effective therapy for many malignant pediatric
brain tumors, contributing substantially to duration of sur-
vival and the chance of cure.
Medulloblastomas are very radiosensitive tumors and
adjuvant therapy with radiation has been the standard of care
in children older than 3 years of age 
15. The reported, long-
term side effects of radiation therapy, such as hearing loss,
cognitive decline, endocrine abnormalities, vascular compli-
cations, as well as secondary malignancies have inspired
many investigators over the years to try to reduce the radia-
tion dose as well as the radiation field 
16–19. The Pediatric
Oncology Group (POG) and Children’s Cancer Group
(CCG) now known as the Children’s Oncology Group
(COG) compared in a prospective trial (POG 631/COG 923)
reduced neuroaxis radiation of 23.6 Gy to the standard regi-
men of 36 Gy with equal posterior fossa  radiation (54 Gy)
for children with average risk medulloblastoma. The interim
analysis indicated an increased risk of early relapse with re-
duced radiation
 20. Since then, many studies have focused on
the introduction of chemotherapy to reduce radiation dose
but maintain adequate survival.
The introduction of conformal radiotherapy enabled ra-
diation oncologists to reduce the radiation field. In previous
treatment strategies after craniospinal irradiation boost ra-
diotherapy was delivered to the complete posterior fossa
 21, 22.
Currently, most investigators used a boost dose to the tumor
bad, instead of irradiating the entire posterior fossa using
conformal radiation therapy with 5-year overall survival
rates of 84% for an average risk-group of patients 
23.
Proton beam therapy is another alternative to conven-
tional radiation therapy. The benefit of using proton beams is
the higher proportion of tumor versus normal tissue distribu-
tion. Proton beam therapy is not currently used in Serbia.
Radiosurgery can successfully be used for local tumor
control in patients with recurrent or residual disease 
24. How-
ever, stereotactic radiation as primary treatment modality is
limited given the propensity of medulloblastomas for dis-
semination and treatment failure can occur due to subclinical
craniospinal metastas.
The current standard for average risk medulloblastoma
includes postoperative craniospinal irradiation of 23.4 Gy,
plus a boost to the posterior fossa of 54 Gy followed by 12
months of chemotherapy. This regimen has resulted in a 5-
year overall survival rates of 80% or better 
25. In high-risk
disease, 36 Gy craniospinal irradiation, plus a boost at the
posterior fossa of 54 Gy, followed by chemotherapy is stan-
dard. Ongoing trials are investigating the benefit of chemo-
therapy during irradiation.
Chemotherapy
There has been a progressive improvement in the re-
sults of treatment of children with medulloblastoma with
overall survival rates of 70% or better
 4, 26.
Reducing the radiation dose without adding chemother-
apy has led to worse outcomes in children with medullo-
blastoma. Many studies have investigated the role of che-
motherapy in addition to radiotherapy with the goal to reduce
the amount of radiation. Different chemotherapeutic agents
has been used and are now standard in the management of
children with medulloblastoma in all risk groups. Alkylators
and platinum compounds such as lomustine, cyclophospha-
mide and cisplatin remain key therapeutic agents. Vincristin
is often administrated weekly during radiotherapy and as
adjuvant chemotherapy. Children with average risk disease,
who were treated with craniospinal radiotherapy of 23.4 Gy
and 55.8 Gy to the posterior fossa, and adjuvant chemotherapy
(lomustine, vincristine and cisplatin) showed a progression-free
survival (PFS) of 86% at 3 year and 79% at 5 years 
27. The
European Hirntumor (HIT) 91 trial compared outcome in pa-
tients with average risk medulloblastoma receiving either
neoadjuvant chemotherapy (prior to radiation therapy) or
postradiation chemotherapy. The 5-year PFS in the postira-
diation chemotherapy arm was 78% and in the neoadjuvant
chemotherapy arm was 65% 
28.
These and some other studies confirm the benefit of
adjuvant chemotherapy for the treatment of average risk
medulloblastoma and regimen reported by Packer 
5  and
Packer et al. 
27 as previously described remains the standard
of therapy for average-risk medulloblastoma patients.
For high-risk medulloblastoma patients, the priority re-
mains to improve survival. Average event-free survival (EFS)
at 5 years for high-risk medulloblastoma ranges from 34% to
40% across studies 
29. Multiple studies have used different
chemotherapy protocols, including neoadjuvant chemotherapy
in combination with surgery and radiation to improve survival
with moderate success 
28. The use of prolonged neoadjuvant
chemotherapy resulted in inferior outcomes compared with
those obtained with shorter times between surgery and radia-
tion therapy 
28, 29. The best outcome for high-risk medullo-
blastoma patients to date was achived by craniospinal irradia-
tion (36 Gy M0-1; 39.6 Gy M2-3) with a boost to the primary
tumor site after maximal surgical resection followed by dose-
intensive cyclophosphamide, vincristine and cisplatin chemo-
therapy with autologous peripheral blood stem rescue. The 5-
year EFS was 70% 
30. The COG (COG 99701) treated 57 pa-
tients with metastatic medulloblastoma with vincristine and
carboplatin while receiving radiation therapy (36 Gy for cra-
niospinal irradiation), followed by monthly treatment with cy-
clophosphamide and vincristine. The 4-year OS and EFS were
reported at 81% and 66%, respectively 
31.
All these studies indicate that chemotherapy is pivotal
for the treatment of high-risk medulloblastoma patients and
ongoing studies are investigating the best regimen for these
patients.Volumen 70, Broj 8 VOJNOSANITETSKI PREGLED Strana 775
Nikitoviý M, Golubiÿiý I. Vojnosanit Pregl 2013; 70(8): 773–777.
Treatment for children less than 3 years of age
Small children with medulloblastoma have poorer sur-
vival than older children when treated with standard radiother-
apy and even more significantly they sustain much greater
treatment-related neurotoxicity. Also, it is believed that med-
ulloblastoma in a very young child have a more aggressive be-
havior and a higher incidence of metastasis at the time of diag-
nosis, although the data is limited. Evans at al. 
32 reported that
34% of children under the age of 4 years presented with dis-
seminated disease compared with only 14% of children aged 4
years or older. Similar results were reported separately with
62% of children less than 5 years of age demonstrating meta-
static disease versus 38% in children older than 5 years of age
 3.
The impact of age on prognosis is difficult to assess be-
cause younger patients normally receive different treatment
modalities than older children. In an attempt to delay or ob-
viate radiation therapy, multiple studies have been performed
using different chemotherapy regimens.
In the mid 1980s, the POG conducted a trial (referred to
as Baby-POG I) enrolling 102 children less than 3 years of age
with brain tumors in which prolonged postoperative chemo-
therapy was given with an attempt to delay radiation therapy.
The 5-year PFS of 62 children with medulloblastoma less than
3 years of age was reported at 31.8% and the 5-year OS at
39.7% using a combination of cyclophosphamide, vincristine,
cis-platinum and etoposide. Radiation was delayed until 3
years of age. The main predictor for survival was extent of
surgical resection. Twenty children undergoing GTR had a 5-
year OS of 60% compared with 33 children who had subtotal
resection and who had a 5-year OS of 32% 
33.
Other studies investigated a similar approach. The CCG
used the “8-in-one-day” regimen followed by either radiation
after two cycles of chemotherapy versus craniospinal irradia-
tion 1 year after diagnosis and completion of maintenance
chemotherapy. Forty-six children with medulloblastoma were
less than 18 months old with 3-year PFS of 22%. Thirty per-
cent were alive and disease-free at a mean follow-up of 72
months
 34. The poorer outcome in the “8-in-one-day” regimen
is probably best explained by the less intensive chemotherapy
regimen in this study compared to the Baby-POG I trial.
Also because of concern for neurotoxicity of radiother-
apy in young children, the use of high-dose ablative chemo-
therapy with autologous bone marrow transplant or stem cell
rescue for children with recurrent or newly diagnosed tumor
is being explored. In view of the chemo-sensitivity of med-
ulloblastoma there have been preliminary studies in which a
small number of newly-diagnosed infants were successfully
treated in consolidation with high-dose chemotherapy sup-
ported by autologous peripheral stem cell rescue; this ap-
proach may have a larger role in treating young children, as
it may for patients who relapse after standard therapy 
35.
Investigational therapy
Better therapy for medulloblastoma undoubtedly will
have its basis in clarification of tumor molecular biology.
Improved understanding of the molecular signature of indi-
vidual tumors will help in determining prognosis and more
accurate tumor risk-stratification, permitting children at
lower risk for recurrence to safety receive less toxic therapy
and reserving more intensive treatment for those at higher-
risk. Knowledge of the molecular defects critical in tumori-
genesis could also provide the means to use them as targets
for novel therapeutic approaches.
A number of studies have identified several possible
molecular traits that could serve as prognostic factors, as
well as potential targets for therapy of medulloblastoma.
Among these are the amplification or overexpression of sev-
eral oncogenes, including epidermal growth factor receptor
B2 (ERBB2),  C-Myc, and N-Myc, loss of caspase-8 expres-
sion, and mutations in several other signal transduction
pathways including the PTCH1/”Sonic Hedgehog” pathway,
“Wingless” (WNT/WG)/beta catenin pathway and platelet-
derived growth factor-alpha (PDGF-a) and RAS/MAP tyro-
sine kinase pathway 
36–39.
Understanding mechanisms of tumorigenesis for future
molecular classification and prognosis is also the first step in
the development of molecular-targeted therapies. Specific
small molecule tyrosine kinase inhibitors could prove effec-
tive against targets in some medulloblastoma (and other
brain tumors). These include imatinib mesylate (Gleevec), a
PDGFa/RAS/MAP tyrosine kinase inhibitor, Erlotinib (Tar-
ceva), which inhibits the oncogene, ERBB2 tyrosine kinase
and Iressa (gefitinib), which inhibits the epidermal growth
factor receptors (EGFR) tyrosin kinase 
39, 40. Some of these
agents are tested in ongoing clinical trials.
The retinoid, cis-retinoic acid, is another therapeutic
agent soon to be evaluated in a randomized fashion in the
upcoming COG protocol for high-risk medulloblas-
toma/PNET tumors. Retinoids mediate apotosis in medullo-
blastoma cells in vitro, and suppres tumor growth in xeno-
graft models
 41.
Conclusion
Childhood medulloblastomas remain a challenging on-
cologic condition.
The main goal for patients with average-risk disease is
to improve morbidity of current treatment regimens and
maintain adequate survival. For patients with high-risk and
recurrent disease, survival remains poor; therefor, improv-
ing outcome is the focus of current investigations. Ad-
vances in understanding molecular profile and associated
clinical outcome will eventually lead to better risk stratifi-
cation and enable neuro-oncologist to better determine risk-
benefit profiles for each individual patient. Therapy for
childhood medulloblastoma requires a delicate balance
between the need to intensify therapy for some group of
patients and the desire to reduce potentially neurotoxic
therapy and risk for other malignancies, so as to have
greater number of survivors with cognitive, psychological
and endocrinologic abilities allowing them to have a better
quality of life.Strana 776 VOJNOSANITETSKI PREGLED Volumen 70, Broj 8
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